Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

“Madrigal is doing a lot of work for us,” said Frederic Cren, CEO of Inventiva Pharma, which has its own oral MASH drug ...

In addition, in the coming years, oral GLP-1 receptor agonists and injectable formulations that require less-frequent ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply ...

The following is a summary of "Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide ...

The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...

MET-233i and Metsera’s other next-generation NuSH analog peptides are also engineered with Metsera’s HALO™ lipidation platform. Oral GLP-1 RA peptide program clinical trial initiated Metsera has ...

Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 -- Announced new ...